• Conference
  • Earn CE
  • Free Samples
  • Magazine
  • Subscribe
  • Videos
    • Recent Quotes
    My Watchlist
    Indicators
    Dental Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Articles published by Tempest Therapeutics

    Tempest Announces Agreement with Roche to Support Advancement of Amezalpat Combination Therapy into First-Line Hepatocellular Carcinoma Pivotal Trial
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Extends Limited Duration Stockholder Rights Plan
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Further Strengthens Leadership Team with Appointment of Sheldon Mullins as Vice President, Regulatory Affairs
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Present at the H.C. Wainwright 26th Annual Global Investment Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Announces the Appointment of Troy M. Wagner as Vice President of Quality Assurance
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Announces Successful End-of-Phase 2 Meeting with FDA for Amezalpat (TPST-1120) to Treat First-Line Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Second Quarter 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Unveils New Survival Data for Amezalpat (TPST-1120) in Randomized First-Line HCC Study Demonstrating a Six-Month Improvement over Control Arm
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Report New Data from Global Randomized Combination Study of Amezalpat (TPST-1120) in First-Line Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Participate in Upcoming Investor Conferences
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports First Quarter 2024 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports New Preclinical Data for TPST-1120 in RCC at the AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Announces Publication of Positive Data from Phase 1 Trial of TPST-1120 in Patients with Advanced Solid Tumors in Journal of Cancer Research Communications
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Year End 2023 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Presents New Data at the SITC 2024 Spring Scientific Meeting Supporting Potent Anti-tumor Activity of TPST-1120 in Multiple Cancer Types
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Announces Upcoming Presentation of Preclinical Data for TPST-1120 in Renal Cell Carcinoma at the AACR Annual Meeting
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Present at the 44th Annual TD Cowen Healthcare Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Present at the 35th Annual Piper Sandler Healthcare Conference
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Reports Third Quarter 2023 Financial Results and Provides Business Update
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Adopts Limited Duration Stockholder Rights Plan
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Releases New Data Demonstrating Superiority of TPST-1120 Arm Across Multiple Study Endpoints in Randomized First-Line HCC Study
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest to Report New and Updated Data from Global Randomized Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Tempest Announces Expanded Role for Sam Whiting, M.D., Ph.D., as Chief Medical Officer and Head of Research and Development
    From Tempest Therapeutics
    Via GlobeNewswire
    Tickers TPST
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.